Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Tonix Pharma (TNXP) is now available.
Tonix Pharmaceuticals has published research indicating that their product, TNX-102 SL, may offer short-term benefits for military-related PTSD, specifically in improving symptoms and sleep quality when administered at bedtime. This finding, which is still in the early phase 3 trial stage, opens up the possibility of using TNX-102 SL in the immediate aftermath of traumatic events for those affected by PTSD. Investors should note that these are forward-looking statements subject to risks and uncertainties, and actual results could differ materially.
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.